JOP20200053A1 - تركيبات كوبانليسيب - Google Patents

تركيبات كوبانليسيب

Info

Publication number
JOP20200053A1
JOP20200053A1 JOP/2020/0053A JOP20200053A JOP20200053A1 JO P20200053 A1 JOP20200053 A1 JO P20200053A1 JO P20200053 A JOP20200053 A JO P20200053A JO P20200053 A1 JOP20200053 A1 JO P20200053A1
Authority
JO
Jordan
Prior art keywords
solution containing
stable
copanlisep
lyophilization
namely
Prior art date
Application number
JOP/2020/0053A
Other languages
English (en)
Inventor
Freundlieb Julia
Jacobs Tia
Original Assignee
Bayer Consumer Care Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63407234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP17207771.1A external-priority patent/EP3498266A1/en
Application filed by Bayer Consumer Care Ag, Bayer Pharma AG filed Critical Bayer Consumer Care Ag
Publication of JOP20200053A1 publication Critical patent/JOP20200053A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Road Signs Or Road Markings (AREA)
  • Luminescent Compositions (AREA)

Abstract

الملخص يتعلق الاختراع الحالي بـ: • طريقة لتحضير محلول حجمي محتوي على الكوبانليسيب مائي ملائم للتجفيد وللتطبيقات العلاجية؛ • محلول حجمي محتوي على الكوبانليسيب، مستقر، ذو ذائبية مرتفعة ملائم للاستخدام مباشرةً في التجفيد؛ • طريقة لتجفيد المحلول الحجمي المائي المحتوي على الكوبانليسيب المذكور؛ • مادة صلبة محتوية على الكوبانليسيب مجفدة ومستقرة، وبالتحديد مسحوق أو كتلة، وتحديداً محتوية على جرعة علاجية من الكوبانليسيب في عبوة واحدة أو اثنتين، وبالتحديد عبوة محكمة الإغلاق واحدة، • طريقة لإعادة تكوين نواتج التجفيد هذه؛ و • محلول محتوي على الكوبانليسيب، معاد تكوينه ومستقر ذو ذائبية مرتفعة، ملائم لخطوة تخفيف إضافية وللتطبيقات العلاجية.
JOP/2020/0053A 2017-09-08 2018-09-06 تركيبات كوبانليسيب JOP20200053A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190117 2017-09-08
EP17207771.1A EP3498266A1 (en) 2017-12-15 2017-12-15 Formulations of copanlisib
PCT/EP2018/073965 WO2019048527A1 (en) 2017-09-08 2018-09-06 COPANLISIB FORMULATIONS

Publications (1)

Publication Number Publication Date
JOP20200053A1 true JOP20200053A1 (ar) 2020-03-08

Family

ID=63407234

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0053A JOP20200053A1 (ar) 2017-09-08 2018-09-06 تركيبات كوبانليسيب

Country Status (36)

Country Link
US (1) US20200281932A1 (ar)
EP (1) EP3678644B1 (ar)
JP (2) JP2020533292A (ar)
KR (1) KR20200052326A (ar)
CN (1) CN111278430A (ar)
AU (1) AU2018328812A1 (ar)
BR (1) BR112020004545A2 (ar)
CA (1) CA3074890A1 (ar)
CL (1) CL2020000584A1 (ar)
CO (1) CO2020002628A2 (ar)
CR (1) CR20200111A (ar)
CU (1) CU24607B1 (ar)
DK (1) DK3678644T3 (ar)
DO (1) DOP2020000054A (ar)
ES (1) ES2950663T3 (ar)
FI (1) FI3678644T3 (ar)
GE (2) GEP20237486B (ar)
HR (1) HRP20230612T1 (ar)
HU (1) HUE063178T2 (ar)
IL (1) IL272857B2 (ar)
JO (1) JOP20200053A1 (ar)
LT (1) LT3678644T (ar)
MA (1) MA50068B1 (ar)
MX (1) MX2020002633A (ar)
NI (1) NI202000019A (ar)
PE (1) PE20200958A1 (ar)
PH (1) PH12020500448A1 (ar)
PL (1) PL3678644T3 (ar)
RS (1) RS64316B1 (ar)
SG (1) SG11202001696QA (ar)
SI (1) SI3678644T1 (ar)
TW (1) TWI794288B (ar)
UA (1) UA126817C2 (ar)
UY (1) UY37868A (ar)
WO (1) WO2019048527A1 (ar)
ZA (1) ZA202002378B (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134943A1 (en) 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
EP4070785B1 (en) * 2021-04-06 2023-11-08 Synthon B.V. Lyophilized composition of copanlisib salt
CN115252613B (zh) * 2022-08-09 2024-01-12 北京清华长庚医院 药物组合物及其在逆转仑伐替尼耐药性中的用途
WO2024069239A1 (en) * 2022-09-28 2024-04-04 Urogen Pharma Ltd. Compositions comprising a thermoreversible hydrogel, and having an extended in-use period

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029055A1 (en) 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
TN2018000271A1 (en) * 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers.
TN2018000272A1 (en) * 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers

Also Published As

Publication number Publication date
US20200281932A1 (en) 2020-09-10
LT3678644T (lt) 2023-06-26
NI202000019A (es) 2020-08-28
SG11202001696QA (en) 2020-03-30
HRP20230612T1 (hr) 2023-09-29
MA50068B1 (fr) 2024-07-31
JP2020533292A (ja) 2020-11-19
KR20200052326A (ko) 2020-05-14
UA126817C2 (uk) 2023-02-08
PH12020500448A1 (en) 2021-02-08
EP3678644A1 (en) 2020-07-15
HUE063178T2 (hu) 2023-12-28
CL2020000584A1 (es) 2020-08-21
FI3678644T3 (fi) 2023-07-28
TWI794288B (zh) 2023-03-01
MX2020002633A (es) 2020-07-13
JP2023071917A (ja) 2023-05-23
UY37868A (es) 2019-04-30
CO2020002628A2 (es) 2020-04-01
AU2018328812A1 (en) 2020-03-12
DK3678644T3 (da) 2023-07-31
CA3074890A1 (en) 2019-03-14
ZA202002378B (en) 2023-10-25
PE20200958A1 (es) 2020-09-24
DOP2020000054A (es) 2020-09-30
PL3678644T3 (pl) 2023-09-11
WO2019048527A1 (en) 2019-03-14
CN111278430A (zh) 2020-06-12
EP3678644B1 (en) 2023-05-03
RS64316B1 (sr) 2023-08-31
IL272857A (en) 2020-04-30
CU20200017A7 (es) 2020-11-30
MA50068A (fr) 2021-06-02
GEP20237486B (en) 2023-03-27
GEAP202215306A (en) 2022-10-25
CU24607B1 (es) 2022-06-06
CR20200111A (es) 2020-07-24
BR112020004545A2 (pt) 2020-09-08
IL272857B2 (en) 2024-03-01
ES2950663T3 (es) 2023-10-11
SI3678644T1 (sl) 2023-08-31
IL272857B1 (en) 2023-11-01
TW201919636A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
ZA202002378B (en) Formulations of copanlisib
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
MX2017005575A (es) Formulacion farmaceutica de anticuerpos anti-tnf alfa.
MX2023003875A (es) Formulacion de una vacuna peptidica.
CY1126334T1 (el) Τυποποιησεις κοπανλισιμπης
MX2016012447A (es) Formulaciones de factor ix liofilizadas.
EA202090731A1 (ru) Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
WO2011151723A3 (en) Concentration of influenza vaccine antigens without lyophilization
CY1121791T1 (el) Καινοτομος σταθερη φαρμακοτεχνικη μορφη
NZ728401A (en) High purity oritavancin and method of producing same
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
CO2017004787A2 (es) Formulación de polvo seco
GB201122430D0 (en) Reconstitution method for high concentration dry protein formulation
AR112753A1 (es) Formulaciones de copanlisib
MX2020002730A (es) Metodos de preparacion de composiciones que contienen timoquinona.
MX2015009141A (es) Formulaciones de albu-bche, preparacion y usos de las mismas.
GR1008818B (el) Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
EA201800311A1 (ru) Способ получения фармацевтической композиции, содержащей бортезомиб, продукт способа
TH177125A (th) สูตรสารวัคซีนโรทาไวรัสที่ถูกทำให้แห้งแบบแช่แข็งที่เสถียรเชิงความร้อน และกรรมวิธีเพื่อเตรียมสิ่งเหล่านั้น
RU2014114462A (ru) Способ получения консервированного корма из биомассы червей